A Phase II Study of RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma

Trial Profile

A Phase II Study of RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 29 Jan 2018

At a glance

  • Drugs Everolimus (Primary) ; Pasireotide (Primary)
  • Indications Uveal melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Jan 2018 According to results published in the Melanoma Research, the study was terminated due to poor accrual.
    • 29 Jan 2018 Status changed from active, no longer recruiting to discontinued, according to results published in the Melanoma Research.
    • 16 Jun 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top